Fig. 1.
Inhibition of normal B-cell proliferation by rituximab.
(A) Resting tonsillar B cells were stimulated in vitro with SAC (open circles) or anti-μ and anti-CD40 (closed circles) in the presence of the indicated concentrations of rituximab. SAC-stimulated cells were also incubated with a control IgG1 antibody (10 μg/mL My7 IgG1) (open square). 3H-thymidine incorporation of quadruplicate wells was measured at 48 to 66 hours. The data are represented as percentage of the stimulated controls in the absence of rituximab. (B) Resting tonsillar B cells were stimulated with SAC and rituximab was added at 2 μg/mL at the indicated times. 3H-thymidine was measured at 48 to 66 hours.
